On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Sunday, August 29, 2010

Transparency - a change about drug approval information on FDA's website

›
I recently noticed that for the approval of the new drugs (NDA) and biological products (BLA), the information about the approval process wa...
3 comments:
Tuesday, August 17, 2010

LOCF, BOCF, WOCF, and MVTF

›
In clinical trials, subjects are usually followed up for a period of time with multiple measurements / assessments at various time points. I...
1 comment:
Saturday, August 07, 2010

R-square for regression without intercept?

›
Sometimes, simple linear regression may not be very simple. One of the issues is to decide whether or not to fit the regression with the int...
1 comment:

Comparing treatment difference in slopes?

›
In regulatory setting, can we show the treatment difference by comparing the slopes between two treatment groups? In a COPD study (e.g., a...
4 comments:
Sunday, June 13, 2010

Biosimilars - Generic Version of Biological Drugs

›
The health reform legislation that was recently signed into law contains a provision that creates a pathway to enable the US Food and Drug ...
Saturday, May 29, 2010

Some clarifications on Non-inferiority (NI) Clinical Trial Design

›
I noted that FDA recently issued its draft guidance on non-inferiority clinical trial design . Two weeks ago, I attended the DIA webinar ...
1 comment:
Sunday, May 16, 2010

Hodges-Lehmann Estimator

›
According to Wikipedia, "the Hodges–Lehmann estimator is a method of robust estimation . The principal form of this estimator is used ...
4 comments:
Sunday, May 09, 2010

Stronger Bioequivalence Standard?

›
In April, 2010, " the Pharmaceutical Science and Clinical Pharmacology Advisory Committee (104715) (PSCPAC) " discussed the issues...
Sunday, May 02, 2010

CDISC beyond the data

›
CDISC stands for the Clinical Data Interchange Standards Consortium. I have always been thinking that the CDISC is about the data standard ...
Sunday, April 18, 2010

China's Regulations on Drug and Biological Products Registration

›
In China, drug and biological products are regulated by SFDA ( 国家食品药品监督管理局 ). sFDA is a counterpart of US FDA. Its Center for Drug Evaluati...
Sunday, April 11, 2010

When to Finalize the Statistical Analysis Plan (SAP)?

›
Recently, a group of statisticians in Linkedin.com (presumabally all working in drug development industry) discussed the following posted q...
9 comments:
Sunday, April 04, 2010

Hockey stick phenomenon

›
Hockey stick phenomenon or hockey stick curves has been used mostly in describing the climate change. it says that the tempeature variation...
Tuesday, March 30, 2010

Health Care Globalization and Patients Without Borders

›
The term 'globalization' is nothing new. According to Wikipedia , "globalization describes an ongoing process by which regional...
Thursday, March 18, 2010

Dealer's choice

›
According to dictionary.com, the term "dealer's choice" is defined as " a card game, as poker, in which the dealer decid...
Saturday, March 13, 2010

Ghost writer, ghost surgeon,...

›
"Ghost writing" practice has been criticized recently due to the reveal of details targeting several big pharmaceutical companies....
Saturday, March 06, 2010

Non-inferiority clinical trials - now comes FDA's draft guidance

›
In contrary to adaptive design clinical trials, non-inferiority (NI) design has been there for many years (15-20 years) and many studies hav...
Thursday, February 25, 2010

Adaptive design clinical trials - now comes the FDA's draft guidance

›
For last several years, 'adaptive design' and 'adaptive clinical trials' are hot topics in biostatistics and clinical trial ...
3 comments:
Friday, February 19, 2010

SAS procedures for group sequential design

›
Group sequential design has been proposed for a while perhaps since Pocock's paper in 1977 . At least for last two decades, the group se...
Sunday, February 14, 2010

Cholesterol Drug Approved for People Without High Cholesterol

›
Are you willing to take Statin medication if you have normal or mild elevation of LDL-Cholesterol level, but with elevated CRP? Last week,...
4 comments:
Monday, February 01, 2010

Cost-benefit analysis: put a dollar value on human life?

›
Putting a Price Tag on Life: Today, companies and governments often use Jeremy Bentham’s utilitarian logic under the name of “cost-benefit a...
6 comments:
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.